# Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori

> **NCT06751121** · PHASE3 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 461 (actual)

## Conditions studied

- Helicobacter Pylori Infection
- Helicobacter Pylori Infected Patients
- Helicobacter Pylori Infected Subjects

## Interventions

- **DRUG:** DWP14012 40mg
- **DRUG:** DWC202301 30mg
- **DRUG:** Amoxicillin 1000mg
- **DRUG:** Clarithromycin 500mg
- **DRUG:** DWC202301 30mg placebo
- **DRUG:** DWP14012 40mg placebo

## Key facts

- **NCT ID:** NCT06751121
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-06
- **Primary completion:** 2025-04-24
- **Final completion:** 2025-04-24
- **Target enrollment:** 461 (ACTUAL)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06751121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06751121, "Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06751121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*